Magnetar Financial Boosts Stake in Neurocrine Biosciences

Institutional investor acquires over 34,000 shares of the biotech company in Q3

Mar. 12, 2026 at 10:34am

Got story updates? Submit your updates here. ›

Magnetar Financial LLC, an institutional investor, acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to a recent SEC filing. The firm purchased 34,071 shares of the company's stock, valued at approximately $4.78 million.

Why it matters

This investment by Magnetar Financial, a prominent hedge fund, signals continued confidence in Neurocrine Biosciences' prospects as a leading biopharmaceutical company focused on treatments for neurological and endocrine disorders. The stock purchase represents a notable increase in Magnetar's exposure to the company.

The details

According to the SEC filing, Magnetar Financial acquired the 34,071 shares of Neurocrine Biosciences in the third quarter. This new position adds to the firm's existing holdings in the biotech company. Neurocrine Biosciences is known for its lead marketed product, Ingrezza, which is approved for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

  • Magnetar Financial acquired the new position in Neurocrine Biosciences during the third quarter of the year.

The players

Magnetar Financial LLC

An institutional investor and hedge fund that has acquired a new position in Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders, and the maker of the approved drug Ingrezza for tardive dyskinesia.

Got photos? Submit your photos here. ›

The takeaway

Magnetar Financial's increased investment in Neurocrine Biosciences reflects the hedge fund's confidence in the biotech company's growth potential and pipeline of neurological and endocrine disorder treatments, particularly its lead product Ingrezza.